WEBULL

The Bull Case For Takeda Pharmaceutical (TSE:4502) Could Change Following New Zasocitinib Phase 3 Psoriasis Data

Simply Wall St · 21h ago
  • In July 2026, Takeda presented new Phase 3 data showing its oral TYK2 inhibitor zasocitinib improved skin clearance in adults with moderate-to-severe plaque psoriasis, including hard-to-treat areas like the scalp, nails, palms and soles.
  • By highlighting high response rates in these high-impact sites while minimizing interaction with other JAK family members, zasocitinib underscores Takeda’s push to differentiate in immunology with targeted, oral therapies.
  • With zasocitinib’s Phase 3 results highlighting strong skin clearance in difficult areas, we’ll explore how this could shape Takeda’s broader investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Takeda Pharmaceutical's Investment Narrative?

For me, the investment case in Takeda hinges on whether you believe its late‑stage pipeline and global scale can eventually translate into sustainable profitability, despite modest revenue growth and a high debt load. The latest Phase 3 data for zasocitinib strengthens the story around immunology as a core growth pillar, but the near‑term share price is still more likely to hinge on upcoming regulatory decisions for drugs like rusfertide and oveporexton, as well as how smoothly the new CEO transition plays out. The Indonesian plasma collaboration looks more like a long‑dated infrastructure and ESG positive than a near‑term earnings driver. Against this, the AMITIZA antitrust verdict and ongoing appeal process remain a key overhang that could influence both cash flow flexibility and capital allocation priorities.

However, one legal overhang could materially affect cash available for shareholders. Takeda Pharmaceutical's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

TSE:4502 1-Year Stock Price Chart
TSE:4502 1-Year Stock Price Chart
Three Simply Wall St Community fair value views span from about ¥6,263 to over ¥15,074, showing a very wide gap in expectations. Against that, investors also have to weigh risks like the large AMITIZA verdict potentially constraining Takeda’s financial flexibility.

Explore 3 other fair value estimates on Takeda Pharmaceutical - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.